Compugen (CGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Compugen (CGEN) has a cash flow conversion efficiency ratio of 0.056x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA4.33 Million ≈ $11.60K USD) by net assets (ILA77.68 Million ≈ $208.26K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Compugen - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Compugen's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CGEN total debt and obligations for a breakdown of total debt and financial obligations.
Compugen Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Compugen ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Berjaya Assets Bhd
KLSE:3239
|
0.032x |
|
Daehan Steel
KO:084010
|
0.015x |
|
Amcil Ltd
AU:AMH
|
0.012x |
|
Xiongan Kerong Environment Technology Co Ltd
SHE:300152
|
-0.004x |
|
X-Legend Entertainment Co Ltd
TW:4994
|
0.036x |
|
Saksoft Limited
NSE:SAKSOFT
|
0.099x |
|
Magnora ASA
OL:MGN
|
-0.110x |
|
Security National Financial
NASDAQ:SNFCA
|
80.269x |
Annual Cash Flow Conversion Efficiency for Compugen (1999–2024)
The table below shows the annual cash flow conversion efficiency of Compugen from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Compugen.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA54.91 Million ≈ $147.22K |
ILA49.60 Million ≈ $132.99K |
0.903x | +265.02% |
| 2023-12-31 | ILA65.56 Million ≈ $175.76K |
ILA-35.89 Million ≈ $-96.21K |
-0.547x | -24.65% |
| 2022-12-31 | ILA77.68 Million ≈ $208.26K |
ILA-34.11 Million ≈ $-91.46K |
-0.439x | -105.95% |
| 2021-12-31 | ILA106.69 Million ≈ $286.04K |
ILA-22.75 Million ≈ $-60.99K |
-0.213x | +9.81% |
| 2020-12-31 | ILA119.78 Million ≈ $321.13K |
ILA-28.32 Million ≈ $-75.92K |
-0.236x | +67.51% |
| 2019-12-31 | ILA38.32 Million ≈ $102.74K |
ILA-27.89 Million ≈ $-74.77K |
-0.728x | -103.92% |
| 2018-12-31 | ILA37.24 Million ≈ $99.85K |
ILA-13.29 Million ≈ $-35.63K |
-0.357x | +65.90% |
| 2017-12-31 | ILA29.30 Million ≈ $78.54K |
ILA-30.66 Million ≈ $-82.19K |
-1.046x | -235.38% |
| 2016-12-31 | ILA63.52 Million ≈ $170.29K |
ILA-19.82 Million ≈ $-53.13K |
-0.312x | -9.54% |
| 2015-12-31 | ILA89.90 Million ≈ $241.01K |
ILA-25.61 Million ≈ $-68.65K |
-0.285x | -170.78% |
| 2014-12-31 | ILA105.97 Million ≈ $284.12K |
ILA-11.15 Million ≈ $-29.89K |
-0.105x | +47.90% |
| 2013-12-31 | ILA31.89 Million ≈ $85.49K |
ILA-6.44 Million ≈ $-17.26K |
-0.202x | +67.10% |
| 2012-12-31 | ILA17.67 Million ≈ $47.38K |
ILA-10.85 Million ≈ $-29.08K |
-0.614x | -29.93% |
| 2011-12-31 | ILA19.58 Million ≈ $52.50K |
ILA-9.25 Million ≈ $-24.80K |
-0.472x | -212.23% |
| 2010-12-31 | ILA28.29 Million ≈ $75.83K |
ILA-4.28 Million ≈ $-11.47K |
-0.151x | +44.39% |
| 2009-12-31 | ILA27.40 Million ≈ $73.45K |
ILA-7.45 Million ≈ $-19.98K |
-0.272x | +72.82% |
| 2008-12-31 | ILA10.00 Million ≈ $26.82K |
ILA-10.01 Million ≈ $-26.84K |
-1.001x | -105.79% |
| 2007-12-31 | ILA17.29 Million ≈ $46.34K |
ILA-8.41 Million ≈ $-22.54K |
-0.486x | -26.03% |
| 2006-12-31 | ILA25.74 Million ≈ $69.00K |
ILA-9.93 Million ≈ $-26.63K |
-0.386x | -25.94% |
| 2005-12-31 | ILA36.25 Million ≈ $97.18K |
ILA-11.11 Million ≈ $-29.78K |
-0.306x | -24.48% |
| 2004-12-31 | ILA49.57 Million ≈ $132.88K |
ILA-12.20 Million ≈ $-32.71K |
-0.246x | -164.19% |
| 2003-12-31 | ILA59.81 Million ≈ $160.34K |
ILA-5.57 Million ≈ $-14.94K |
-0.093x | +29.28% |
| 2002-12-31 | ILA68.88 Million ≈ $184.67K |
ILA-9.08 Million ≈ $-24.33K |
-0.132x | -11.08% |
| 2001-12-31 | ILA80.06 Million ≈ $214.64K |
ILA-9.50 Million ≈ $-25.46K |
-0.119x | -78.69% |
| 2000-12-31 | ILA92.51 Million ≈ $248.02K |
ILA-6.14 Million ≈ $-16.46K |
-0.066x | +85.27% |
| 1999-12-31 | ILA12.79 Million ≈ $34.28K |
ILA-5.76 Million ≈ $-15.45K |
-0.451x | -- |
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical tria… Read more